2023


  1. Lutfullin I, Eveslage M, Bittner S, Antony G, Flaskamp M, Luessi F, Salmen A, Gisevius B, Klotz L, Korsukewitz C, Berthele A, Groppa S, Then Bergh F, Wildemann B, Bayas A, Tumani H, Meuth SG, Trebst C, Zettl UK, Paul F, Heesen C, Kuempfel T, Gold R, Hemmer B, Zipp F, Wiendl H, Lünemann JD (2023). Association of obesity with disease outcome in multiple sclerosis. J Neurol Neurosurg Psychiatry, 94(1), 57-61.
     
  2. Duchow A, Bellmann-Strobl J, Friede T, Aktas O, Angstwurm K, Ayzenberg I, Berthele A, Dawin E, Engels D, Fischer K, Flaskamp M, Giglhuber K, Grothe M, Havla J, Hümmert MW, Jarius S, Kaste M, Kern P, Kleiter I, Klotz L, Korporal-Kuhnke M, Kraemer M, Krumbholz M, Kümpfel T, Lohmann L, Ringelstein M, Rommer P, Schindler P, Schubert C, Schwake C, Senel M, Then Bergh F, Tkachenko D, Tumani H, Trebst C, Vardakas I, Walter A, Warnke C, Weber MS, Wickel J, Wildemann B, Winkelmann A, Paul F, Stellmann JP (2023). Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD. Ann Neurol, 0, 0.
     
  3. Hümmert MW, Stern C, Paul F, Duchow A, Bellmann-Strobl J, Ayzenberg I, Schwake C, Kleiter I, Hellwig K, Jarius S, Wildemann B, Senel M, Berthele A, Giglhuber K, Luessi F, Grothe M, Klotz L, Schülke R, Gingele S, Faiss JH, Walter A, Warnke C, Then Bergh F, Aktas O, Ringelstein M, Stellmann JP, Häußler V, Havla J, Pellkofer H, Kümpfel T, Kopp B, Trebst C (2023). Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study). Mult Scler, 29(7), 819-831.
     
  4. Hümmert MW, Bütow F, Tkachenko D, Ayzenberg I, Pakeerathan T, Hellwig K, Klotz L, Häußler V, Stellmann JP, Warnke C, Goereci Y, Etgen T, Luessi F, Bronzlik P, Gingele S, Lauenstein AS, Kleiter I, Rommer PS, Paul F, Bellmann-Strobl J, Duchow A, Then Bergh F, Pul R, Walter A, Pellkofer H, Kümpfel T, Pompsch M, Kraemer M, Albrecht P, Aktas O, Ringelstein M, Senel M, Giglhuber K, Berthele A, Jarius S, Wildemann B, Trebst C (2023). Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study. Neurol Neuroimmunol Neuroinflamm, 10(2), 200082-.
     
  5. Schwake C, Pakeerathan T, Kleiter I, Ringelstein M, Aktas O, Korporal-Kuhnke M, Wildemann B, Jarius S, Bayas A, Pul R, Ceylan U, Faissner S, Hellwig K, Ayroza Galvao Ribeiro Gomes AB, Lipps P, Pröbstel AK, Kümpfel T, Oswald E, Then Bergh F, Gödel C, Hümmert MW, Trebst C, Gold R, Ayzenberg I (2023). Humoral COVID-19 vaccine response in patients with NMOSD/MOGAD during anti-IL-6 receptor therapy compared to other immunotherapies. Mult Scler, 29(6), 757-761.
     
  6. Salmen A, Hoepner R, Fleischer V, Heldt M, Gisevius B, Motte J, Ruprecht K, Schneider R, Fisse AL, Grüter T, Lukas C, Berthele A, Giglhuber K, Flaskamp M, Mühlau M, Kirschke J, Bittner S, Groppa S, Lüssi F, Bayas A, Meuth S, Heesen C, Trebst C, Wildemann B, Then Bergh F, Antony G, Kümpfel T, Paul F, Nischwitz S, Tumani H, Zettl U, Hemmer B, Wiendl H, Zipp F, Gold R (2023). Factors associated with depressive mood at the onset of multiple sclerosis - an analysis of 781 patients of the German NationMS cohort. Ther Adv Neurol Disord, 16(), 17562864231197309.
     
  7. Singer BA, Arnold DL, Drulovic J, Freedman MS, Gold R, Gudesblatt M, Jasinska E, LaGanke CC, Naismith RT, Negroski D, Oh J, Hernandez Perez MA, Selmaj K, Then Bergh F, Wundes A, Ziemssen T, Castro-Borrero W, Chen H, Levin S, Scaramozza M, Shankar SL, Wang T, Wray S (2023). Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler, 29(14), 1795-1807.
     


    8. 2022


  8. Schinke C, Rullmann M, Luthardt J, Drabe M, Preller E, Becker GA, Patt M, Regenthal R, Zientek F, Sabri O, Then Bergh F, Hesse S (2022). HPA Axis Responsiveness Associates with Central Serotonin Transporter Availability in Human Obesity and Non-Obesity Controls. Brain Sci, 12(11), 1-18.
     
  9. Hamann J, Ettrich B, Hoffman KT, Then Bergh F, Lobsien D (2022). Somatosensory evoked potentials and their relation to microstructural damage in patients with multiple sclerosis-A whole brain DTI study. Front Neurol, 13(), 890841.
     
  10. Wray S, Then Bergh F, Wundes A, Arnold DL, Drulovic J, Jasinska E, Bowen JD, Negroski D, Naismith RT, Hunter SF, Gudesblatt M, Chen H, Lyons J, Shankar SL, Kapadia S, Mendoza JP, Singer BA (2022). Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study. Adv Ther, 39(4), 1810-1831.
     
  11. Endres D, Lüngen E, Hasan A, Kluge M, Fröhlich S, Lewerenz J, Bschor T, Haußleiter IS, Juckel G, Then Bergh F, Ettrich B, Kertzscher L, Oviedo-Salcedo T, Handreka R, Lauer M, Winter K, Zumdick N, Drews A, Obrocki J, Yalachkov Y, Bubl A, von Podewils F, Schneider U, Szabo K, Mattern M, Philipsen A, Domschke K, Wandinger KP, Neyazi A, Stich O, Prüss H, Leypoldt F, Tebartz van Elst L (2022). Clinical manifestations and immunomodulatory treatment experiences in psychiatric patients with suspected autoimmune encephalitis: a case series of 91 patients from Germany. Mol Psychiatry, 27(3), 1479-1489.
     
  12. Fleischer V, Ciolac D, Gonzalez-Escamilla G, Grothe M, Strauss S, Molina Galindo LS, Radetz A, Salmen A, Lukas C, Klotz L, Meuth SG, Bayas A, Paul F, Hartung HP, Heesen C, Stangel M, Wildemann B, Then Bergh F, Tackenberg B, Kümpfel T, Zettl UK, Knop M, Tumani H, Wiendl H, Gold R, Bittner S, Zipp F, Groppa S, Muthuraman M (2022). Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. Ann Neurol, 91(2), 192-202.
     


    13. 2021


  13. Seelmann-Eggebert H, Stoppe M, Then Bergh F, Classen J, Rumpf JJ (2021). Motor Sequence Learning across Multiple Sessions Is Not Facilitated by Targeting Consolidation with Posttraining tDCS in Patients with Progressive Multiple Sclerosis. Neural Plast, 2021(), 6696341.
     
  14. Neuhaus O, Köhler W, Then Bergh F, Kristoferitsch W, Faiss J, Rosenkranz T, Reske D, Patejdl R, Hartung HP, Zettl UK (2021). Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue-Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers. Biomolecules, 11(3), -.
     
  15. Ostkamp P, Salmen A, Pignolet B, Görlich D, Andlauer TFM, Schulte-Mecklenbeck A, Gonzalez-Escamilla G, Bucciarelli F, Gennero I, Breuer J, Antony G, Schneider-Hohendorf T, Mykicki N, Bayas A, Then Bergh F, Bittner S, Hartung HP, Friese MA, Linker RA, Luessi F, Lehmann-Horn K, Mühlau M, Paul F, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber F, Wildemann B, Zettl UK, Ziemann U, Müller-Myhsok B, Kümpfel T, Klotz L, Meuth SG, Zipp F, Hemmer B, Hohlfeld R, Brassat D, Gold R, Gross CC, Lukas C, Gr (2021). Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proc Natl Acad Sci U S A, 118(1), -.
     


    16. 2020


  16. Schmidt E, Schinke C, Rullmann M, Luthardt J, Becker GA, Haars S, Stoppe M, Lobsien D, Hoffmann KT, Sabri O, Hesse S, Then Bergh F (2020). Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients. Sci Rep, 10(1), 14651.
     
  17. Bittner S, Steffen F, Uphaus T, Muthuraman M, Fleischer V, Salmen A, Luessi F, Berthele A, Klotz L, Meuth SG, Bayas A, Paul F, Hartung HP, Linker R, Heesen C, Stangel M, Wildemann B, Then Bergh F, Tackenberg B, Kuempfel T, Weber F, Zettl UK, Ziemann U, Tumani H, Groppa S, Mühlau M, Lukas C, Hemmer B, Wiendl H, Gold R, Zipp F (2020). Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine, 56(), 102807.
     
  18. Gasperi C, Andlauer TFM, Keating A, Knier B, Klein A, Pernpeintner V, Lichtner P, Gold R, Zipp F, Then Bergh F, Stangel M, Tumani H, Wildemann B, Wiendl H, Bayas A, Kümpfel T, Zettl UK, Linker RA, Ziemann U, Knop M, Warnke C, Friese MA, Paul F, Tackenberg B, Berthele A, Hemmer B (2020). Genetic determinants of the humoral immune response in MS. Neurol Neuroimmunol Neuroinflamm, 7(5), 827.
     
  19. Engel S, Graetz C, Salmen A, Muthuraman M, Toenges G, Ambrosius B, Bayas A, Berthele A, Heesen C, Klotz L, Kümpfel T, Linker RA, Meuth SG, Paul F, Stangel M, Tackenberg B, Then Bergh F, Tumani H, Weber F, Wildemann B, Zettl UK, Antony G, Bittner S, Groppa S, Hemmer B, Wiendl H, Gold R, Zipp F, Lill CM, Luessi F (2020). Is APOE ?4 associated with cognitive performance in early MS? Neurol Neuroimmunol Neuroinflamm, 7(4), 1.
     


    20. 2019


  20. Stoppe M, Meyer K, Schlingmann M, Olbrich S, Then Bergh F (2019). Hyperstable arousal regulation in multiple sclerosis. Psychoneuroendocrinology, 110, 104417-.
     
  21. van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernandez I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleo A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illan-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morr (2019). A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathol, 138, 237-250.
     
  22. Hoyer A, Then Bergh F, Klaeske K, Lehmann S, Misfeld M, Borger M, Dieterlen MT (2019). Custodiol-N? cardioplegia lowers cerebral inflammation and activation of hypoxia-inducible factor-1?. Interact Cardiovasc Thorac Surg, 28(6), 884-892.
     
  23. Schinke C, Hesse S, Rullmann M, Becker GA, Luthardt J, Zientek F, Patt M, Stoppe M, Schmidt E, Meyer K, Meyer PM, Orthgiess J, Bluher M, Kratzsch J, Ding YS, Then Bergh F, Sabri O (2019). Central noradrenaline transporter availability is linked with HPA axis responsiveness and copeptin in human obesity and non-obese controls. Stress, 22(1), 93-102.
     


    24. 2018


  24. Rumpf JJ, Dietrich S, Stoppe M, Fricke C, Weise D, Then Bergh F, Classen J (2018). Compromised tDCS-induced facilitation of motor consolidation in patients with multiple sclerosis. J Neurol, 265, 2302-2311.
     
  25. von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kumpfel T, Stangel M, (2018). Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurol Neuroimmunol Neuroinflamm, 5, 446.
     
  26. Branzan D, Etz CD, Moche M, Von Aspern K, Staab H, Fuchs J, Then Bergh F, Scheinert D, Schmidt A (2018). Ischaemic preconditioning of the spinal cord to prevent spinal cord ischaemia during endovascular repair of thoracoabdominal aortic aneurysm: first clinical experience. EuroIntervention, 14, 828-835.
     
  27. Heine J, Pruss H, Kopp UA, Wegner F, Then Bergh F, Munte T, Wandinger KP, Paul F, Bartsch T, Finke C (2018). Beyond the limbic system: disruption and functional compensation of large-scale brain networks in patients with anti-LGI1 encephalitis. J Neurol Neurosurg Psychiatry, 89, 1191-1199.
     
  28. Schinke C, Hesse S, Rullmann M, Becker GA, Luthardt J, Zientek F, Patt M, Stoppe M, Schmidt E, Meyer K, Meyer PM, Orthgiess J, Bluher M, Kratzsch J, Ding YS, Then Bergh F, Sabri O (2018). Central noradrenaline transporter availability is linked with HPA axis responsiveness and copeptin in human obesity and non-obese controls. Stress, 29, 1-10.
     


    29. 2017


  29. Stoppe M, Busch M, Krizek L, Then Bergh F (2017). Outcome of MS relapses in the era of disease-modifying therapy. BMC Neurol, 17(1), 151.
     
  30. Schinke C, Hesse S, Stoppe M, Meyer K, Schmidt E, Orthgiess J, Bechmann L, Bresch A, Rullmann M, Luthardt J, Sabri O, Bluher M, Kratzsch J, Then Bergh F (2017). Post-dexamethasone serum copeptin corresponds to HPA axis responsiveness in human obesity. Psychoneuroendocrinology, 78, 39-47.
     
  31. Schwartzbach CJ, Grove RA, Brown R, Tompson D, Then Bergh F, Arnold DL (2017). Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study. J Neurol, 264(2), 304-315.
     
  32. Finke C, Pruss H, Heine J, Reuter S, Kopp UA, Wegner F, Then Bergh F, Koch S, Jansen O, Munte T, Deuschl G, Ruprecht K, Stocker W, Wandinger KP, Paul F, Bartsch T (2017). Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies. JAMA Neurol, 74(1), 50-59.
     


    33. 2014


  33. Stoppe M, Thoma E, Liebert UG, Major EO, Hoffmann KT, Classen J, Then Bergh F (2014). Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis. J Neurol, 261(5), 1021-1024.
     
  34. Bechmann L, Busse K, Stoppe M, Cotte S, Ettrich B, Then Bergh F (2014). Corticosteroid receptor expression and in vivo glucocorticoid sensitivity in multiple sclerosis. J Neuroimmunol, 276(1-2), 159-165.
     
  35. Lobsien D, Ettrich B, Sotiriou K, Classen J, Then Bergh F, Hoffmann KT (2014). Whole-brain diffusion tensor imaging in correlation to visual-evoked potentials in multiple sclerosis: a tract-based spatial statistics analysis. AJNR Am J Neuroradiol, 35(11), 2076-2081.
     
  36. Kumpfel T, Schwan M, Weber F, Holsboer F, Trenkwalder C, Then Bergh F (2014). Hypothalamo-pituitary-adrenal axis activity evolves differentially in untreated versus treated multiple sclerosis. Psychoneuroendocrinology, 45, 87-95.
     
  37. Werner P, Fritzsch D, Holland H, Bauer M, Krupp W, Hoffmann KT, Saur D, Then Bergh F, Sabri O, Barthel H (2014). Definition of primary and secondary glioblastoma-letter. Clin Cancer Res, 20(7), 2011-2012.
     


    38. 2013


  38. Conradi S, Malzahn U, Paul F, Quill S, Harms L, Then Bergh F, Ditzenbach A, Georgi T, Heuschmann P, Rosche B (2013). Breastfeeding is associated with lower risk for multiple sclerosis. Mult Scler, 19(5), 553-558.
     


    39. 2012


  39. Schneider M, Eichfeld U, Beller A, Baum P, Classen J, Then Bergh F (2012). Myasthenia gravis and thymolipoma: a rare variation of a well-known theme]. Nervenarzt, 83(8), 1035-1038.
     


    40. 2010


  40. Gunther P, Baum P, Then Bergh F, Hermann W (2010). [Wilson's disease and multiple sclerosis] Nervenarzt, 81(2), 226-228.
     
  41. Thomae E, Niklas A, Sebraouri H, Baum P, Wagner A, Then Bergh F (2010). "Improving Test-Retest Variability of Visual-Evoked Responses in Multiple Sclerosis" J Clin Neurophysiol, 27(4), 270-273.
     
  42. Michalski D, Liebig S, Thomae E, Singer S, Hinz A, Then Bergh F (2010). Anxiety, depression and impaired health-related quality of life are therapeutic challenges in patients with multiple sclerosis Mental Illness, 2, e5.
     


    43. 2009


  43. Niklas A, Sebraoui H, Heß E, Wagner A, Then Bergh F (2009). Outcome measures for trials of remyelinating agents in multiple sclerosis: retrospective longitudinal analysis of visual evoked potential latency. Multiple Sclerosis, 15(1), 68-74.
     


    44. 2007


  44. Strecker K, Schneider JP, Sabri O, Wegner F, Then Bergh F, Schwarz J, Hesse S (2007). Responsiveness to a dopamine agent in Holmes tremor - case report. Eur J Neurol, 14(4), e9-e10.
     
  45. Then Bergh F (2007). The clock keeps ticking for intravenous methylprednisolone. J Neurol Neurosurg Psychiatry, 78(8), 788-.
     
  46. Then Bergh F, Kumpfel T, Yassouridis A, Lechner C, Holsboer F, Trenkwalder C (2007). Acute and chronic neuroendocrine effects of interferon-beta 1a in multiple sclerosis. Clin Endocrinol (Oxf), 66(2), 295-303.
     


    47. 2006


  47. Then Bergh F, Niklas A, Strauss A, von Ahsen N, Niederwieser D, Schwarz J, Wagner A, Al-Ali HK (2006). Rapid progression of Myelodysplastic syndrome to acute myeloid leukemia on sequential azathioprine, IFN-beta and copolymer-1 in a patient with multiple sclerosis. Acta Haematol, 116(3), 207-210.
     
  48. Schneider JP, Reinohs M, Prothmann S, Puccini S, Dalitz B, Schwarz J, Zimmer C, Then Bergh F (2006). Subcortical Right Parietal AVM Rotational vertigo and caloric stimulation fMRI support a parietal representation of vestibular input. J Neurol, 253(2), 253-255.
     
  49. Then Bergh F, Kumpfel T, Schumann E, Held U, Schwan M, Blazevic M, Wismuller A, Holsboer F, Yassouridis A, Uhr M, Weber F, Daumer M, Trenkwalder C, Auer DP (2006). Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol, 6, 19.
     


    50. 2004


  50. Then Bergh F, Dayyani F, Ziegler-Heitbrock L (2004). Impact of type-I-interferon on monocyte subsets and their differentiation to dendritic cells. An in vivo and ex vivo study in multiple sclerosis patients treated with interferon-beta. J Neuroimmunol, 146(1-2), 176-188.